Claritas Pharmaceuticals, Inc. (CLAZF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -309 Thousand | -6.48 Million | -4.84 Million | -5.56 Million |
| Net Income | - | - | 4.21 Million | -21.21 Million | 6.93 Million | -31.86 Million |
| Depreciation & Amortization | - | - | 18.01 Million | 33.32 Million | - | - |
| Deferred income taxes | - | - | -5.14 Million | -11.25 Thousand | - | - |
| Stock-based compensation | - | - | 344.00 | 3148.00 | 875 Thousand | 346 Thousand |
| Change in working capital | - | - | -5.56 Million | -4.39 Million | 1.11 Million | -690 Thousand |
| Other non-cash items | - | - | -12.04 Million | -15.12 Million | -13.77 Million | 26.64 Million |
| Investing Cash Flow | - | - | 2105.65 | -188 Thousand | - | -10 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | -10 Million |
| Investment purchases | - | - | - | -8185.99 | - | - |
| Sales/Maturities of investments | - | - | 2105.65 | - | - | - |
| Other Investing Activities | - | - | 2.00 | -179.81 Thousand | - | - |
| Financing Cash Flow | - | - | 294.79 Thousand | 6.47 Million | 1.38 Million | 18.57 Million |
| Debt repayment | - | - | -71.59 Thousand | -200 Thousand | - | -4.12 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 6.18 Million | 3.23 Million | 14.57 Million |
| Other Financing Activities | - | - | 366.38 Thousand | 492 Thousand | -1.84 Million | -127.17 Thousand |
| Accounts receivables | - | - | -89.49 Thousand | 408.27 Thousand | -387.19 Thousand | -94.27 Thousand |
| Accounts payables | - | - | -483 Thousand | 358 Thousand | 1.18 Million | -769 Thousand |
| Inventory | - | - | -108.5 Thousand | -537.27 Thousand | 544.19 Thousand | 793.81 Thousand |
| Other working capital | - | - | -4.88 Million | -4.62 Million | -219.99 Thousand | 173.27 Thousand |
| Cash at beginning of period | - | 5000.00 | 32 Thousand | 227 Thousand | 3.68 Million | 673 Thousand |
| Cash at end of period | - | 5000.00 | -12.1 Thousand | 32 Thousand | 227 Thousand | 3.68 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | -31.99 Thousand | - | - | - |
| Net cash flow / Change in cash | - | - | -44.1 Thousand | -195 Thousand | -3.45 Million | 3.01 Million |
| Free Cash Flow | - | - | -309 Thousand | -6.48 Million | -4.84 Million | -5.56 Million |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | - | - |
| Other non-cash items | - | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | - | - | - | - | - | - |
| Cash at end of period | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
EMITF
GROV
3020
VENUSPIPES
KASHYAP
KOPRAN